{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:18:47Z","timestamp":1778635127114,"version":"3.51.4"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CDJKXB14011"],"award-info":[{"award-number":["CDJKXB14011"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CDJZR14468801"],"award-info":[{"award-number":["CDJZR14468801"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2018CDQYSG0007"],"award-info":[{"award-number":["2018CDQYSG0007"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["10611CDJXZ238826"],"award-info":[{"award-number":["10611CDJXZ238826"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2018QNA7023"],"award-info":[{"award-number":["2018QNA7023"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Project on Industrial Generic Key Technologies of Chongqing","award":["cstc2015zdcy-ztzx120003"],"award-info":[{"award-number":["cstc2015zdcy-ztzx120003"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC0910500"],"award-info":[{"award-number":["2018YFC0910500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872798"],"award-info":[{"award-number":["81872798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004\u201317, each with information about drug clinical trial dated back to 1984. Analysis of the clinical trial timelines of these targets may reveal the trial-speed differentiating features for facilitating target assessment. Here we present a comprehensive analysis of all these 89 targets, following the earlier studies for prospective prediction of clinical success of the targets of clinical trial drugs. Our analysis confirmed the literature-reported common druggability characteristics for clinical success of these innovative targets, exposed trial-speed differentiating features associated to the on-target and off-target collateral effects in humans and further revealed a simple rule for identifying the speedy human targets through clinical trials (from the earliest phase I to the 1st drug approval within 8\u00a0years). This simple rule correctly identified 75.0% of the 28 speedy human targets and only unexpectedly misclassified 13.2% of 53 non-speedy human targets. Certain extraordinary circumstances were also discovered to likely contribute to the misclassification of some human targets by this simple rule. Investigation and knowledge of trial-speed differentiating features enable prioritized drug discovery and development.<\/jats:p>","DOI":"10.1093\/bib\/bby130","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T12:29:07Z","timestamp":1545308947000},"page":"649-662","source":"Crossref","is-referenced-by-count":144,"title":["Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs"],"prefix":"10.1093","volume":"21","author":[{"given":"Ying Hong","family":"Li","sequence":"first","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"},{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]},{"given":"Xiao Xu","family":"Li","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"},{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]},{"given":"Jia Jun","family":"Hong","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"}]},{"given":"Yun Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"}]},{"given":"Jian Bo","family":"Fu","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]},{"given":"Chun Yan","family":"Yu","sequence":"additional","affiliation":[{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]},{"given":"Feng Cheng","family":"Li","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[{"name":"School of International Studies, Zhejiang University, Hangzhou, China"}]},{"given":"Wei Wei","family":"Xue","sequence":"additional","affiliation":[{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]},{"given":"Yu Yang","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong, China"}]},{"given":"Yu Zong","family":"Chen","sequence":"additional","affiliation":[{"name":"Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore, Singapore"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China"},{"name":"Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China"}]}],"member":"286","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"2020080709362538100_ref1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2132","article-title":"Drugs, their targets and the nature and number of drug targets","volume":"5","author":"Imming","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.58.2.4","article-title":"Therapeutic targets: progress of their exploration and investigation of their characteristics","volume":"58","author":"Zheng","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2020080709362538100_ref4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fphar.2018.01245","article-title":"Determining the balance between drug efficacy and safety by the network and biological system profile of its therapeutic target","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2020080709362538100_ref5","doi-asserted-by":"crossref","first-page":"D1069","DOI":"10.1093\/nar\/gkv1230","article-title":"Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information","volume":"44","author":"Yang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref6","doi-asserted-by":"publisher","DOI":"10.2174\/1871520618666181029132017","article-title":"What makes species productive of anti-cancer drugs? Clues from drugs' species origin, druglikeness, target and pathway","author":"Li","year":"2018","journal-title":"Anticancer Agents Med Chem"},{"key":"2020080709362538100_ref7","doi-asserted-by":"crossref","first-page":"D1121","DOI":"10.1093\/nar\/gkx1076","article-title":"Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics","volume":"46","author":"Li","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.clpt.6100363","article-title":"Beyond genomics","volume":"82","author":"Dollery","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2020080709362538100_ref9","doi-asserted-by":"crossref","first-page":"W162","DOI":"10.1093\/nar\/gkx449","article-title":"NOREVA: normalization and evaluation of MS-based metabolomics data","volume":"45","author":"Li","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fphar.2018.00681","article-title":"Discovery of the consistently well-performed analysis chain for SWATH-MS based pharmacoproteomic quantification","volume":"9","author":"Fu","year":"2018","journal-title":"Front Pharmacol"},{"key":"2020080709362538100_ref11","doi-asserted-by":"crossref","first-page":"38881","DOI":"10.1038\/srep38881","article-title":"Performance evaluation and online realization of data-driven normalization methods used in LC\/MS based untargeted metabolomics analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"2020080709362538100_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bby127","article-title":"ANPELA: analysis and performance-assessment of the label-free quantification workflow for metaproteomic studies","author":"Tang","year":"2018","journal-title":"Brief Bioinform"},{"key":"2020080709362538100_ref13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1568026023394317","article-title":"Application of high-throughput, molecular-targeted screening to anticancer drug discovery","volume":"2","author":"Shoemaker","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"2020080709362538100_ref14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.drudis.2006.06.017","article-title":"Synthetic library design","volume":"11","author":"Huwe","year":"2006","journal-title":"Drug Discov Today"},{"key":"2020080709362538100_ref15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrd2220","article-title":"A decade of fragment-based drug design: strategic advances and lessons learned","volume":"6","author":"Hajduk","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2017.12.002","article-title":"Clinical success of drug targets prospectively predicted by in silico study","volume":"39","author":"Zhu","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"2020080709362538100_ref19","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1021\/jm049131r","article-title":"Druggability indices for protein targets derived from NMR-based screening data","volume":"48","author":"Hajduk","year":"2005","journal-title":"J Med Chem"},{"key":"2020080709362538100_ref20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt1273","article-title":"Structure-based maximal affinity model predicts small-molecule druggability","volume":"25","author":"Cheng","year":"2007","journal-title":"Nat Biotechnol"},{"key":"2020080709362538100_ref21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/acschemneuro.7b00490","article-title":"What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation","volume":"9","author":"Xue","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"2020080709362538100_ref22","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1039\/C7CP07869B","article-title":"Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder","volume":"20","author":"Xue","year":"2018","journal-title":"Phys Chem Chem Phys"},{"key":"2020080709362538100_ref23","doi-asserted-by":"crossref","first-page":"29513","DOI":"10.1039\/C8CP06232C","article-title":"Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by an escitalopram scaffold","volume":"20","author":"Zheng","year":"2018","journal-title":"Phys Chem Chem Phys"},{"key":"2020080709362538100_ref24","first-page":"2766","article-title":"Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD","volume":"2017","author":"Wang","year":"1861","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2020080709362538100_ref25","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/acschemneuro.7b00173","article-title":"Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"2020080709362538100_ref26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/jpet.108.149955","article-title":"What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets","volume":"330","author":"Zhu","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2020080709362538100_ref27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1101\/gr.6888208","article-title":"Quantitative systems-level determinants of human genes targeted by successful drugs","volume":"18","author":"Yao","year":"2008","journal-title":"Genome Res"},{"key":"2020080709362538100_ref28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nbt1338","article-title":"Drug-target network","volume":"25","author":"Yildirim","year":"2007","journal-title":"Nat Biotechnol"},{"key":"2020080709362538100_ref29","doi-asserted-by":"crossref","first-page":"20558","DOI":"10.1038\/srep20558","article-title":"The exploration of network motifs as potential drug targets from post-translational regulatory networks","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"2020080709362538100_ref30","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1109\/TMM.2018.2838320","article-title":"A fast uyghur text detector for complex background images","volume":"20","author":"Yan","year":"2018","journal-title":"IEEE Trans Multimedia"},{"key":"2020080709362538100_ref31","article-title":"Cross-modality bridging and knowledge transferring for image understanding","author":"Yan","year":"2018","journal-title":"IEEE Trans Multimedia"},{"key":"2020080709362538100_ref32","doi-asserted-by":"crossref","first-page":"D787","DOI":"10.1093\/nar\/gkp1014","article-title":"Update of TTD: Therapeutic Target Database","volume":"38","author":"Zhu","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrd3160","article-title":"Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years","volume":"9","author":"Braun","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2020080709362538100_ref35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2014.1361","article-title":"Prevalence, characteristics, and publication of discontinued randomized trials","volume":"311","author":"Kasenda","year":"2014","journal-title":"JAMA"},{"key":"2020080709362538100_ref36","first-page":"1","article-title":"Contract and budget process top cause of study delay","volume":"12","author":"CenterWatch","year":"2005","journal-title":"The CenterWatch Monthly"},{"key":"2020080709362538100_ref37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/rheumatology\/29.3.211","article-title":"Failure of selenium-ace to improve osteoarthritis","volume":"29","author":"Hill","year":"1990","journal-title":"Br J Rheumatol"},{"key":"2020080709362538100_ref38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database\u2014update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"key":"2020080709362538100_ref39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref40","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkx1121","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY","volume":"46","author":"Harding","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref41","doi-asserted-by":"crossref","first-page":"W29","DOI":"10.1093\/nar\/gkt282","article-title":"BLAST: a more efficient report with usability improvements","volume":"41","author":"Boratyn","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref42","doi-asserted-by":"crossref","first-page":"D279","DOI":"10.1093\/nar\/gkv1344","article-title":"The Pfam protein families database: towards a more sustainable future","volume":"44","author":"Finn","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref43","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over the tree of life","volume":"43","author":"Szklarczyk","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2020080709362538100_ref44","doi-asserted-by":"crossref","first-page":"14438","DOI":"10.1038\/srep14438","article-title":"Graph theoretic network analysis reveals protein pathways underlying cell death following neurotropic viral infection","volume":"5","author":"Ghosh","year":"2015","journal-title":"Sci Rep"},{"key":"2020080709362538100_ref45","doi-asserted-by":"crossref","first-page":"2509385","DOI":"10.1155\/2016\/2509385","article-title":"Comparison of FDA approved kinase targets to clinical trial ones: insights from their system profiles and drug-target interaction networks","volume":"2016","author":"Xu","year":"2016","journal-title":"Biomed Res Int"},{"key":"2020080709362538100_ref46","article-title":"The human kinome targeted by FDA approved multi-target drugs and combination products: A comparative study from the drug-target interaction network perspective","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"2020080709362538100_ref47","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"2020080709362538100_ref48","first-page":"1057","article-title":"A protein network descriptor server and its use in studying protein, disease, metabolic and drug targeted networks","volume":"18","author":"Zhang","year":"2017","journal-title":"Brief Bioinform"},{"key":"2020080709362538100_ref49","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00214-009-0670-5","article-title":"TissueDistributionDBs: a repository of organism-specific tissue-distribution profiles","volume":"125","author":"Kogenaru","year":"2010","journal-title":"Theor Chem Acc"},{"key":"2020080709362538100_ref51","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/nar\/gky092","article-title":"UniProt: the universal protein knowledgebase","volume":"46","author":"The UniProt Consortium","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2020080709362538100_ref52","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1038\/srep04782","article-title":"Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor","volume":"4","author":"Turetsky","year":"2014","journal-title":"Sci Rep"},{"key":"2020080709362538100_ref53","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1101\/gr.152322.112","article-title":"Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance","volume":"23","author":"Jia","year":"2013","journal-title":"Genome Res"},{"key":"2020080709362538100_ref54","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/092986711796391705","article-title":"Irreversible protein kinase inhibitors","volume":"18","author":"Garuti","year":"2011","journal-title":"Curr Med Chem"},{"key":"2020080709362538100_ref55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref56","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1185\/030079906X132415","article-title":"Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials","volume":"22","author":"Machado","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2020080709362538100_ref57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.archger.2007.01.049","article-title":"Drug adverse events and drop-out risk: a clinical case","volume":"44","author":"Scoyni","year":"2007","journal-title":"Arch Gerontol Geriatr"},{"key":"2020080709362538100_ref58","first-page":"2123","article-title":"Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials","volume":"26","author":"Weinblatt","year":"1999","journal-title":"J Rheumatol"},{"key":"2020080709362538100_ref59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10897-013-9642-y","article-title":"Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience","volume":"23","author":"DeWard","year":"2014","journal-title":"J Genet Couns"},{"key":"2020080709362538100_ref60","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S1470-2045(12)70539-9","article-title":"Which drug, and when, for patients with BRAF-mutant melanoma?","volume":"14","author":"Jang","year":"2013","journal-title":"Lancet Oncol"},{"key":"2020080709362538100_ref61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","article-title":"PCSK9: from discovery to therapeutic applications","volume":"107","author":"Farnier","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"2020080709362538100_ref62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2020080709362538100_ref63","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"2020080709362538100_ref64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"2020080709362538100_ref65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd4611","article-title":"Changes in clinical trial length","volume":"14","author":"Pregelj","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2020080709362538100_ref66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.phrs.2015.09.019","article-title":"Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs","volume":"102","author":"Tao","year":"2015","journal-title":"Pharmacol Res"},{"key":"2020080709362538100_ref67","doi-asserted-by":"crossref","first-page":"E7301","DOI":"10.1073\/pnas.1705441114","article-title":"In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer","volume":"114","author":"Kodama","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020080709362538100_ref68","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31098","article-title":"Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins","volume":"7","author":"Martinko","year":"2018","journal-title":"Elife"},{"key":"2020080709362538100_ref69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature19791","article-title":"Accurate de novo design of hyperstable constrained peptides","volume":"538","author":"Bhardwaj","year":"2016","journal-title":"Nature"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/21\/2\/649\/33582786\/bby130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/21\/2\/649\/33582786\/bby130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:48:25Z","timestamp":1596808105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/21\/2\/649\/5290023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,23]]},"published-print":{"date-parts":[[2020,3,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bby130","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,1,23]]}}}